October 1, 2012
Today, fool.com health-care analysts Brenton Flynn and David Williamson examine Pharmacyclics' September drop and look to explain the move. The company saw a huge run-up in August that raises the stakes for success. David cautions that a slip-up will send shares spiraling, as the company still doesn't have its potentially blockbuster drug in phase 3 trials at this time.
When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.